Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
Authors
Keywords
-
Journal
Clinical and Molecular Hepatology
Volume 26, Issue 3, Pages 328-339
Publisher
The Korean Association for the Study of the Liver
Online
2020-05-28
DOI
10.3350/cmh.2019.0049n
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort
- (2019) Bernhard Scheiner et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Nivolumab for hepatocellular carcinoma (HCC) in a real-world context.
- (2019) Nisha Rao et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series
- (2019) Swetha Kambhampati et al. CANCER
- Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan
- (2019) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
- (2019) Thomas Yau et al. JOURNAL OF HEPATOLOGY
- Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice
- (2018) Shinsuke Uchikawa et al. HEPATOLOGY RESEARCH
- Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
- (2018) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
- (2018) Masafumi Ikeda et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA26Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)
- (2018) M J Pishvaian et al. ANNALS OF ONCOLOGY
- Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma
- (2018) Changhoon Yoo et al. INVESTIGATIONAL NEW DRUGS
- Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers
- (2018) Fabian Finkelmeier et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention
- (2018) Zhenqiu Liu et al. JOURNAL OF HEPATOLOGY
- Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation
- (2017) Hye Won Lee et al. Gut and Liver
- Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population
- (2017) Jonggi Choi et al. HEPATOLOGY
- AASLD guidelines for the treatment of hepatocellular carcinoma
- (2017) Julie K. Heimbach et al. HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
- (2017) Duan Feng et al. Oncotarget
- Cause of death in patients with hepatocellular carcinoma (HCC) according to Barcelona Clinic Liver Cancer System (BCLC): Tumor versus nontumor-related mortality.
- (2017) A. K. Dip Borunda et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria
- (2016) Jeong-Hoon Lee et al. ANNALS OF SURGERY
- Outcome and cause of death of hepatocellular carcinoma patients with extrahepatic metastases.
- (2015) Satoshi Shiba et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognosis of untreated hepatocellular carcinoma
- (2014) Edoardo G. Giannini et al. HEPATOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More